Low pO2 and β-estradiol induce VEGF in MCF-7 and MCF-7-5C cells: Relationship to in vivo hypoxia

Breast Cancer Research and Treatment

Volumn 67, Issue 1, 2001, Pages 51-60

  Maity, Amit ^a   Sall, Walter ^a   Koch, Cameron J ^a   Oprysko, Patricia R ^a   Evans, Sydney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Hypoxia; MCF 7; VEGF

Indexed keywords

2 NITROIMIDAZOLE; ESTRADIOL; MESSENGER RNA; VASCULOTROPIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; OXYGEN; TAMOXIFEN; TUMOR PROTEIN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL HYPOXIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; BREAST TUMOR; CELL CULTURE; DRUG EFFECT; METABOLISM; PRESSURE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL HYPOXIA; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; FEMALE; HUMANS; LYMPHOKINES; MICE; MICE, NUDE; NEOPLASM PROTEINS; OXYGEN; PARTIAL PRESSURE; TAMOXIFEN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034742473     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010662905549     Document Type: Article

References (57)

1. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
2. Current status of knowledge and critical issues in tumor oxygenation. Results from 25 years research in tumor pathophysiology
3. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
4. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
5. Oxygenation predicts radiation response and survival in patients with cervix cancer
6. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
7. Tamoxifen induces hypoxia in MCF-7 xenografts
8. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
9. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
10. VEGFs, receptors and angiogenesis
11. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
12. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
13. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
14. Clinical significance of angiogenic factors in breast cancer
15. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
16. 2 homeostasis
17. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen
18. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
19. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors
20. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis
21. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
22. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells
23. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells
24. Tamoxifen, raloxifene, and the prevention of breast cancer
25. Cloning of a novel receptor expressed in rat prostate and ovary
26. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol
27. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts
28. A thin-film culturing technique allowing rapid gas-Liquid equilibration (6 sec) with no toxicity to mammalian cells
29. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
30. Increased stability and transcription both contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia
31. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: Analysis of drug adducts by fluorescent antibodies versus bound radioactivity
32. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors
33. Detection of hypoxia in human squamous cell carcinoma by EF5 binding
34. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
35. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
36. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
37. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
38. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
39. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line
40. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor
41. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth
42. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
43. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
44. Etiology of human breast cancer: A review
45. Menopause and breast cancer risk
46. Age at first birth and breast cancer risk
47. Reproductive factors in the aetiology of breast cancer
48. Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai Breast Cancer Study
49. Menstrual influence on surgical cure of breast cancer
50. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer
51. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival
52. Effect of menstrual phase on surgical treatment of breast cancer
53. Timing of surgery with regard to the menstrual cycle in women with primary breast cancer
54. Vascular endothelial growth factor in premenopausal women-Indicator of the best time for breast cancer surgery?
55. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture
56. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
57. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer